Clinical Trial Update: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL [Phase 3]

View source ↗

Summary

Phase 3 trial comparing acalabrutinib with obinutuzumab and venetoclax versus obinutuzumab and venetoclax in previously untreated high-risk chronic lymphocytic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Calquence (acalabrutinib) (acalabrutinib)
• Gazyva (obinutuzumab) (obinutuzumab)
• Venclexta (venetoclax) (venetoclax)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: RECRUITING